Ulinastatin-Fc (Samsung Bioepis/Takeda)

N/A

Report date: 2025/04/20 20:00:03

Base Information

Drug NameUlinastatin-Fc (Samsung Bioepis/Takeda)
Drug Alias NameSB-26UTI-FcTAK-671
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionImmunomodulatorsTrypsin inhibitors
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTakeda Pharmaceutical Co LtdSamsung Bioepis Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTakeda Pharmaceutical Co LtdSamsung Bioepis Co Ltd
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A
Related LinksN/A